期刊
PEPTIDES
卷 77, 期 -, 页码 28-37出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2015.08.013
关键词
Bariatric; Ghrelin; Gastrin; Cholecystokinin; Incretin; Oxyntomodulin
资金
- Wellcome Trust [WT084210Z/07/Z, WT088357Z/09/Z]
- MRC [MRC_MC_UU_12012/3]
- Full4Health (FP7) [266408]
- Wellcome Trust Translational Medicine and Therapeutics Programme - Wellcome Trust
- Glaxo SmithKline
- MRC [MC_UU_12012/3] Funding Source: UKRI
- Medical Research Council [MC_UU_12012/3] Funding Source: researchfish
- Wellcome Trust [106263/Z/14/Z] Funding Source: researchfish
Bariatric surgery for obesity has proved to be an extremely effective method of promoting long-term weight reduction with additional beneficial metabolic effects, such as improved glucose tolerance and remission of type 2 diabetes. A range of bariatric procedures are in common use, including gastric banding, sleeve gastrectomy and the Roux-en-Y gastric bypass. Although the mechanisms underlying the efficacy of bariatric surgery are unclear, gastrointestinal and pancreatic peptides are thought to play an important role. The aim of this review is to summarise the effects of different bariatric surgery procedures upon gastrointestinal and pancreatic peptides, including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic hormone (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin, insulin, glucagon and somatostatin. (C) 2015 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据